Pages that link to "Q44013109"

The following pages link to Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition (Q44013109):

Displaying 44 items.

• Antipsychotic medication for early episode schizophrenia (Q24236683) (← links)
• Interventions to reduce weight gain in schizophrenia (Q24243093) (← links)
• Antidepressants for the negative symptoms of schizophrenia (Q24245099) (← links)
• Management of antipsychotic-related weight gain (Q24610124) (← links)
• Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia (Q24798487) (← links)
• Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis (Q27691321) (← links)
• Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis (Q27692023) (← links)
• Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia (Q28080437) (← links)
• Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis (Q28292187) (← links)
• Current options in the management of olanzapine-associated weight gain (Q31138909) (← links)
• World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia (Q33235110) (← links)
• World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects (Q34315836) (← links)
• Psychosis in elderly patients: classification and pharmacotherapy (Q34543627) (← links)
• Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (Q34623350) (← links)
• Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis (Q34661011) (← links)
• Weight gain and new onset diabetes associated with olanzapine and risperidone (Q34733828) (← links)
• Management of atypical antipsychotic drug-induced weight gain: focus on metformin (Q34983478) (← links)
• Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. (Q35031175) (← links)
• Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. (Q35090012) (← links)
• Weight gain profiles of new anti-psychotics: public health consequences (Q35198895) (← links)
• Antipsychotic treatment in schizophrenia: atypical options and NICE guidance (Q35202844) (← links)
• Pharmacotherapy to limit weight gain caused by antipsychotic use (Q35548146) (← links)
• Schizophrenia and weight management: a systematic review of interventions to control weight. (Q35553266) (← links)
• Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. (Q36034676) (← links)
• First-episode schizophrenia: a focus on pharmacological treatment and safety considerations (Q36133796) (← links)
• Antipsychotic-induced weight gain (Q36211002) (← links)
• Medications associated with weight gain (Q36309632) (← links)
• Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review (Q36377890) (← links)
• Interventions for the metabolic syndrome in schizophrenia: a review (Q36401248) (← links)
• Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications (Q36577866) (← links)
• Pharmacological management of atypical antipsychotic-induced weight gain. (Q37165503) (← links)
• Schizophrenia, obesity, and antipsychotic medications: what can we do? (Q37226376) (← links)
• Post-graduate CME (Q37334124) (← links)
• Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain (Q37710237) (← links)
• A systematic review of metformin to limit weight-gain with atypical antipsychotics (Q37854834) (← links)
• Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients (Q44357531) (← links)
• [Efficacy of behavioural lifestyle interventions for weight management of psychiatric patients]. (Q45209540) (← links)
• Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial (Q46534674) (← links)
• Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats (Q47302385) (← links)
• Quality of life issues associated with antipsychotic-induced weight gain (Q47441133) (← links)
• The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment (Q49481418) (← links)
• Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia (Q51500381) (← links)
• Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study (Q57709401) (← links)
• Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance (Q61798233) (← links)